A phase 1/2 study of vadastuximab talirine (SGN-CD33A) in combination with azacitidine in patients with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High risk myelodysplastic syndrome (MDS) - Regional Cancer Care Associates LLC

Clinical Trials

A phase 1/2 study of vadastuximab talirine (SGN-CD33A) in combination with azacitidine in patients with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High risk myelodysplastic syndrome (MDS)

Type of Cancer
Myelodysplastic Syndrome
Locations
Bethesda
Sponsor
Seattle Genetics, Inc.
Protocol Number
SGN33A-004
Cancer Diagnosis
To Learn More Call
201-510-0910